WAYNE, Pa. and MISGAV, Israel, June 5, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that the first patient has been enrolled in its Phase 1/2 clinical trial of MDGN-201 (EPODURETM).
Help employers find you! Check out all the jobs and post your resume.
